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Mechanism of Lck Activation in Driving Leukemia Cell Proliferation
Hannah Dobson, Yixin Cui, Li Li, and Gongqin Sun, Department of Cell and Molecular Biology, University of Rhode Island.

Introduction

Methods
DH5α E. coli cell stock stored at -80°C, containing a pGEX vector with the
wild type Lck gene was subcultured in 4 mL of LB liquid medium and
allowed to grow overnight while shaking at 250 rpm in 37°C. From these
cells, the plasmid containing Lck was isolated using QIAprep Spin Miniprep
Kit (Qiagen). Subsequent DNA sequencing confirmed the presence of the
wild type Lck gene correctly cloned in the reading frame of the N-terminal
GST affinity tag.
To purify wild type Lck enzyme, the plasmid was transformed into DH5α
cells and streaked on LB agar ampicillin plates and incubated overnight.
Transformed colonies were subcultured in 500 mL of LB liquid medium
containing 50 "g/mL of ampicillin and allowed to grow overnight while
shaking at 250 rpm in 37°C. After 12 hours, the culture was brought to room
temperature and IPTG 50 "g/mL was added to induce Lck expression for 6
hours. The cells were spun down at 5000 g for 30 minutes and the pellet
saved at -20°C. Cell pellets were thawed and resuspended on ice in PBS lysis
buffer. To lyse the cells, the cell mixture was passed through a French
Pressure cell press 3 times. The lysate was then subjected to centrifugation at
20,000 rpm at 4°C for 30 minutes. Supernatant was then incubated with 0.06
g of glutathione-agarose beads (Sigma) while shaking at 4°C for 2 hours.
This lysate supernatant was passed through an empty chromatography
column, washed 3 times with protocols specific for the GST-affinity tag, and
finally Lck was eluted from the column. Enzyme concentration was
quantified using the Bradford assay according to a standard BSA curve.
We used the QuikChange protocol to
generate the Lck mutants from the wild
type Lck plasmid and also engineered a
substrate specific for Lck. Each
QuikChange reaction was transformed
into fresh competent DH5α E. coli cells.
The plasmids for the mutants were
isolated and DNA sequence was
confirmed. The same purification
protocol was used for each mutant and
substrate as described above.
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Lck contains a linker region located between its SH2 and kinase domains.
Previous studies have shown that the linker plays an important inhibitory
role in regulating Lck activation through its interaction with the SH3 and
kinase domains. With this regulatory mechanism, we hypothesized that the
Pinsert mutation in the linker region would disrupt Lck’s ability to adopt the
inhibitory conformation resulting in increased enzymatic activity. Our
preliminary results in figure 5demonstrate that the Pinsert Lck mutation
does indeed activate Lck.
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Figure 5. Western blot of wild type Lck (lanes 1-3) and Pinsert
Lck (lanes 4-6) enzymatic activity. Enzyme concentrations: lanes
one and two 0.02 mg/mL, lanes two and five 0.05 mg/mL , and
lanes three and six 0.2 mg/mL. The same concentration of Lck
substrate was used for each lane.

Figure 5 shows the relative ability of each enzyme to phosphorylate the Lck
substrate and also undergo autophosphorylation. The phosphorylation on Lck
and the Lck mutant was determined by Western Blot using an antibody against
phosphotyrosine. Lane 3 and lane 6 show the phosphorylation of wt Lck and
the Lck insertion mutant and their ability to phosphorylate the Lck substrate. At
an enzyme concentration of 0.2 mg/, the Lck band staining levels are
comparable between the two lanes, indicating that the two enzymes have a
similar ability to autophosphorylate. The significantly darker band at the
substrate level in lane six demonstrates that the Pinsert Lck mutant was more
active in phosphorylating the substrate than the wild type Lck at the same
enzyme concentration. This result indicates that the Pinsert Lck mutant is more
active than the wild type enzyme.

% of Viable Cells Remaining

In the leukemia cancer cell line CTV-1, researchers
have identified four characteristic mutations in the
Lck gene. As a member of the Src family kinases,
Lck plays an integral role in regulating growth and
division in immune system cells. Leukemia
develops when a mutational event alters a white
blood cell’s differentiation pattern and causes the
cell to divide without control. As white blood cells
Figure 1. Lck
xx blood, they affect healthy cell function. With Lck’s
begin accumulating in the
role in signaling for cell division, we hypothesized that the identified
mutations result in Lck’s constitutive activation causing leukemia
progression. In order to determine how these mutations affect Lck
activation, we used molecular techniques to introduce each mutation into a
normally functioning Lck enzyme, engineered a substrate specific for Lck,
and demonstrated that one of the mutations activates Lck function. This
research lays a foundation for understanding the oncogenic basis of the
CTV-1 cancer cell.

Discussion

Results

Inhibition of CTV-1 Cell Proliferation by Targeted Drugs
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Figure 6. Inhibition of CTV-1 cells by targeted drug therapies. Beginning at a
concentration of 0.0006 uM, each drug was added at concentrations increasing by a
factor of 10 until the max concentration of 20 uM. Cells were incubated with each drug
for 72 hours before data collection. Data is courtesy of Dr. Li Li M.D. Ph.D. and Dr.
Gongquin Sun Ph.D.

Figure 2. Illustration of pGEX plasmid.

A kinase assay was performed with Lck to test for wild type activity, while a
western blot was used to test enzymatic phosphorylation of the Lck
substrate by the wildtype and mutant enzyme.

Figure 7. Ribbon structure of wild type Lck with domains labeled.
The red region connecting the SH2 domain to the kinase domain
is linker region.
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Data in figure 6 show that A770041 was most effective in blocking CTV-1 cell
proliferation. Although Bosutinib, Dasatinib and A770041 all target Src
family kinases, A770041 shows the strongest inhibition. Considering that
CTV-1 cells contain mutations only in Lck, and not in other Src family
kinases like Src and Fyn, we believe A770041 is suppressing mutant Lck
activity. Together these data suggest that the Pinsert mutation in Lck found
in CTV-1 cells causes the enzyme’s constitutive activation, uncontrolled cell
proliferation, and therefore leukemia progression.

To determine if the activated Lck is responsible for the proliferation of CTV-1
cells, we determined the sensitivity of CTV-1 cells to various kinase inhibitors
that have different levels of inhibition for Lck. The results are shown in figure 6..
Bosutinib, Dasatinib and A770041 are Src family inhibitors with A770041 being
the most selective inhibitor for Lck. Sorafenib targets FLT3, an unrelated kinase,
and was used as a control. A770041 displayed an IC50 (concentration killing
50% of the cells ) of.8 nM. Bosutinib, dasatinib, displayed IC50 values of 18 and
3.6 nM. In contrast sorafenib has an IC50 of 7000 nM toward CTV-1. These
results demonstrate that Lck is activated in CTV-1 cells and the activated Lck is
responsible for CTV-1 proliferation.
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